Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Neostigmine Action Pathway (new)
Homo sapiens
Drug Action Pathway
Neostigmine is a cholinesterase inhibitor used in the symptomatic treatment of myasthenia gravis by improving muscle tone.
Cholinergic neurons in the brain are primarily responsible for movement in skeletal muscles. In the neuron, acetylcholine is synthesized from acetyl-coa and choline, and stored into synaptic vesicles. When an action potential arrives at the nerve terminal, voltage-gated calcium channels open leading to an influx of calcium ions into the neuron. This triggers the docking of the synaptic vesicle and the release of acetylcholine into the synapse. Acetylcholine acts on nicotinic receptors on the motor end plate. Nicotinic receptors are cation channels, when activated they transport sodium ions into the motor end plate. The sodium causes depolarization of the cell, opening voltage-gated calcium channels on the sarcoplasmic reticulum. Calcium enters the cytosol from the sarcoplasmic reticulum and binds to calmodulin. Calmodulin activates myosin light chain kinase. Myosin light chain kinase converts myosin light chain to phosphorylated myosin light chain. The phosphorylated myosin light chain causes actin to become bound to myosin leading to muscle contraction. The acetylcholine in the synapse is cleared rapidly by acetylcholinesterase which breaks acetylcholine down into choline and acetate. Choline is taken back up into the presynaptic neuron and recycled to produce more acetylcholine. Neostigmine reversibly inhibits the acetylcholinesterase enzyme, which normally breaks down acetylcholine. The main pharmacological actions of this drug are believed to occur as the result of this enzyme inhibition, enhancing cholinergic transmission, which improves muscle tone.
Common side effects include bradyarrhythmias, bronchospasm, miosis, nausea, and increased peristalsis.
References
Neostigmine Pathway (new) References
Luo J, Chen S, Min S, Peng L: Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade. Ther Clin Risk Manag. 2018 Dec 10;14:2397-2406. doi: 10.2147/TCRM.S179420. eCollection 2018.
Pubmed: 30573962
Valle RG, Godoy FL: Neostigmine for acute colonic pseudo-obstruction: A meta-analysis. Ann Med Surg (Lond). 2014 Jun 19;3(3):60-4. doi: 10.1016/j.amsu.2014.04.002. eCollection 2014 Sep.
Pubmed: 25568788
Neely GA, Sabir S, Kohli A: Neostigmine.
Pubmed: 29261883
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings